Navigation Links
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Date:11/20/2012

CAMBRIDGE, Mass., Nov. 20, 2012 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat genetically defined cancers, today announced the publication of a contemporary review on targeting protein methyltransferases for personalized cancer therapeutics in the Nature Publishing Group journal Oncogene.

"This publication provides a comprehensive review of the histone methyltransferase (HMT) target class, the genetic alterations in these enzymes that drive specific human cancers and the ongoing efforts to identify and develop potent, selective inhibitors of these enzymes as the basis for novel, personalized cancer therapeutics," said Robert Copeland, Ph.D., Executive Vice President and Chief Scientific Officer of Epizyme. "The review highlights the significant progress that has been made in this field over the past five years and provides a clear foundation for the clinical development of HMT inhibitors (HMTi) that is now underway."

Epizyme has identified 96 histone methyltransferases and determined that 20 play an important role in cancer; these are prime targets for drug development. The company's programs to develop inhibitors for DOT1L for MLL-rearranged leukemia and EZH2 for mutant-bearing Non-Hodgkin lymphoma are examples of Epizyme's approach to creating personalized therapeutics for these genetically defined cancers.

The paper titled, "Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics," was authored by Robert A. Copeland, Mikel P. Moyer and Victoria M. Richon at Epizyme, and is available online.

About Epizyme

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a class of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.

Epizyme has benchmark alliances with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.

Media Contact
Megan Lustig
Spectrum
202.955.6222 ext. 2586
mlustig@spectrumscience.com


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
2. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
3. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
4. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
5. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
6. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
7. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
8. Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
11. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 According ... titled "Global Market Study on Automated Endoscope Reprocessors: Single Basin ... CAGR of 8.6% Between 2016 and 2024 " the global automated endoscope ... is expected to expand at a CAGR of 7.2% during ... of US$ 1,367.6 Mn by 2024. ...
(Date:12/2/2016)... ATLANTA , Dec. 2, 2016 Quantum ... screening and expert radiologist interpretation directly to women at ... partners with corporations, such as Delta Air Lines and ... cancer screening as a component of wellness initiatives. ... women of SunTrust. It enables them to have a ...
(Date:12/2/2016)... , December 2, 2016 ... Awards Committee honored excellence in research, development and innovation ... The gala dinner was held in the presence of ... the Russian Federation , Natalia Sanina, ... Mikhail Murashko , Head of Roszdravnadzor, National Service ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
Breaking Medicine News(10 mins):